CTRI/2011/11/002104招募中未知
A randomized, multiple site, open label, two treatment, two period, two sequence, multiple-dose, crossover, bioequivalence study of Etoposide 50mg Capsules of Banner Pharmacaps, USA compared with Etoposide 50mg Capsules of Mylan Inc., USA in adult patients with small cell lung cancer under fasting steady-state conditions
试验速览
- 阶段
- 未知
- 状态
- 招募中
- 入组人数
- 24
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Ba/be
入排标准
入选标准
- •Male or female patients aged 18years of age or older.
- •Patients already receiving etoposide and expected to receive at least two additional cycles at the same dose.
- •Eastern Cooperative Oncology Group (ECOG) performance status < 2.
- •Life expectancy > 3 months.
排除标准
- •The patients will be excluded from study, if they meet any of the following criteria:
- •Hypersensitivity to Etoposide or related class of drugs.
- •Extensive disease treatable with radiotherapy.
- •Past or current history of other malignant disease.
- •Concurrent severe medical problems other than small cell lung cancer.
- •Patients with central nervous system metastases receiving more than 12 mg /day dexamethasone or equivalent to control symptoms.
- •Patient had a clinically significant history of cardiac disease;
- •Patient had pre-existing severe motor or sensory neuropathy higher than grade 1, according to the National Cancer Institute Common Toxicity Criteria (CTC) Scale (34); had active infections or other serious concomitant medical conditions that would impair the ability of a patient to receive the protocol treatment;
- •Patients with low serum albumin.
- •Patient had dementia.
- •Women who are unwilling or unable to use an acceptable method to avoid pregnancy for the entire study period for a least 1 month before and at least 3 months after the completion of the study.
- •Women using a prohibited contraceptive method.
- •Women who are pregnant or breastfeeding.
- •Men whose sexual partners are women who are of childbearing potential, and who are unwilling or unable to use an acceptable method to avoid pregnancy of his partner for the entire study period as outlined above.
- •Known CYP450 strong inhibitors2 such as atazanavir, clarithromycin, indinavir, itraconazole, ketoconazole, nefazodone, nelfinavir, ritonavir, saquinavir or telithromycin and well known inducers2 such as rifampin, carbamazepine, rifabutin, rifapentin, dexamethasone, phenytoin, phenobarbital, and St. Johns wort within 1 month of the study starting.
- •History or presence of significant alcoholism or drug abuse in the past one year.
- •History or presence of significant smoking (more than 10 cigarettes or beediâ??s/day).
- •History or presence of asthma, urticaria or other significant allergic reactions.
- •History or presence of significant gastric and/or duodenal ulceration.
- •History or presence of significant thyroid disease, adrenal dysfunction, organic intracranial lesion such as pituitary tumor.
- •Difficulty with donating blood.
- •Difficulty in swallowing solids like tablets or capsules.
- •Patients with any other condition which in the Investigators opinion would not make the patient a good candidate for the clinical trial.
- •Severe medical problems other than the cancer that would limit the ability of the patient to follow study guidelines or expose the patient to extreme risk.
- •Participation in a drug research study within past 3 months.
- •Donation of blood in the past 3 months before screening.
- •Positive screening test for any one or more: HIV, Hepatitis B and Hepatitis C.
- •History or presence of significant easy bruising or bleeding.
- •History or presence of significant recent trauma.
研究者
相似试验
招募中
不适用
A randomized, open label, multi centric, 2 treatment, 2 period, 2 sequence, single dose, crossover, BE study of Paclitaxel protein-bound particles for injectable suspension 100mg/vial and Abraxane 100mg/vial (Albumin bound Paclitaxel 260mg/m2) IV infusion in patients with metastatic breast cancerCTRI/2015/03/005653Actavis LLC60
已完成
不适用
A study to evaluate the safety of Doxorubicin from Panacea Biotech Ltd (test drug) in comparison to the Doxorubicin of Sun Pharmaceuticals Ind. Ltd. (reference drug) in ovarion cancer patientsCTRI/2017/03/008179Panacea Biotech Ltd32
已完成
不适用
Comparative BE study of Everolimus 10 mg tablet OD manufactured by Par Pharmaceutical,NY 10977,USA with Afinitor10 mg tablet manufactured by Novartis Pharma Stein AG Stein, Switzerland in Advanced Renal Cell Carcinoma patients under fasting condition.CTRI/2014/02/004394Par PharmaceuticalInc48
招募中
不适用
A clinical study to assess the comparative blood concentration of two anti-cancer drugs (test and marketed Paclitaxel) in patients with breast cancerCTRI/2018/08/015506Teva Pharmaceuticals USA
暂停
不适用
Bioequivalence study of Paliperidone Palmitate in schizophrenia patientsCTRI/2019/02/017754Amneal Pharmaceuticals Company GmbH